These 2 ASX Healthcare Stocks Are Quietly Cashing In on the AI Revolution

ASX Healthcare Stocks Benefiting From AI

Artificial intelligence is reshaping healthcare faster than most investors realise. Hospital imaging systems, pathology labs, and diagnostic platforms are all being transformed by AI tools that improve speed, cut costs, and expand margins. Yet most of the market is still looking at chipmakers and data centres for AI exposure. For ASX investors, that creates a genuine opportunity. Two healthcare companies in particular are worth understanding this week.

What are the Best ASX Healthcare Stocks to invest in right now?

Check our buy/sell tips

Mach7 Technologies: The Infrastructure Layer Powering AI Imaging at Scale

Mach7 Technologies (ASX: M7T) builds the software platform that connects medical imaging data across entire hospital networks. Think of it as the plumbing that lets AI diagnostic tools actually reach patients. Without infrastructure like Mach7’s, AI tools developed for radiology and imaging cannot be deployed at scale across a hospital system.

What makes this investment case genuinely interesting is the stickiness of the business. Once a large hospital network is live on Mach7’s platform, switching to a competitor is extremely costly and disruptive. Analysts have highlighted this enterprise stickiness as a key differentiator. It is the kind of competitive moat that is hard for rivals to dislodge.

The business is also maturing financially. Mach7 delivered revenue of approximately A$33.8 million in FY25, up around 16% on the prior year. The company was operating cash flow positive for three consecutive quarters and closed the year with A$23.1 million in cash and no debt. A recent contract win with UnityPoint Health in the United States shows the commercial pipeline is still moving forward.

We believe Mach7 is a high-growth platform story with real moat characteristics. It suits growth investors who are comfortable waiting for full profitability as the enterprise contract base expands. The key thing to watch is new contract announcements, particularly in the US market, where the largest health systems represent transformational opportunities.

Sonic Healthcare: Using AI to Expand Margins Inside a Defensive Business

Sonic Healthcare (ASX: SHL) is one of the world’s largest pathology and radiology providers, operating across Australia, the US, Germany, Switzerland, and the UK. It is not a speculative AI play. It is a profitable, dividend-paying compounder that is now embedding AI directly into its lab operations to drive efficiency and margin improvement.

Through partnerships with Harrison.ai and Franklin.ai, Sonic is deploying AI tools across anatomical pathology workflows, including chest X-ray analysis and CT brain applications. Bell Potter considers Sonic the most advanced AI integrator in its analyst coverage and expects meaningful margin expansion to flow through over the next two years as these tools scale.

The recent numbers back this up. For the six months ended December 2025, Sonic reported revenue of A$5.45 billion, up 17%, with EBITDA margins expanding year on year. Full-year FY26 earnings guidance was reaffirmed, implying up to 13% EBITDA growth over FY25. The stock surged close to 10% on results day in February as investors took notice. Sonic also pays a 60% franked dividend with a trailing yield of around 5%, making it one of the few growth stocks that doubles as an income play.

The Investor’s Takeaway for ASX Healthcare Stocks

AI in healthcare is not a future promise. It is driving revenue and margins for both companies right now.
Mach7 and Sonic offer two very different entry points into the same structural theme. Mach7 is the higher-growth platform play for investors willing to wait for profitability. Sonic is the lower-risk compounder for investors who want AI exposure alongside earnings visibility and income. In our view, owning both gives investors the full range of this theme without putting all the risk in one place.